<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006669</article-id><article-id pub-id-type="pmc">PMC11860196</article-id><article-id pub-id-type="doi">10.3390/vaccines13020122</article-id><article-id pub-id-type="publisher-id">vaccines-13-00122</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The <italic toggle="yes">Salmonella</italic> Paratyphi A O-Antigen Glycoconjugate Vaccine Is Able to Induce Antibodies with Bactericidal Activity Against a Panel of Clinical Isolates</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-4088-0483</contrib-id><name><surname>Pinto</surname><given-names>Marika</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00122" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Durante</surname><given-names>Salvatore</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00122" ref-type="aff">2</xref><xref rid="fn1-vaccines-13-00122" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6633-567X</contrib-id><name><surname>Carducci</surname><given-names>Martina</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Massai</surname><given-names>Luisa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7103-0723</contrib-id><name><surname>Alfini</surname><given-names>Renzo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2638-0713</contrib-id><name><surname>Mylona</surname><given-names>Elli</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-vaccines-13-00122" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Karkey</surname><given-names>Abhilasha</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-vaccines-13-00122" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Stephen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-vaccines-13-00122" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Micoli</surname><given-names>Francesca</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6112-6841</contrib-id><name><surname>Giannelli</surname><given-names>Carlo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0170-1285</contrib-id><name><surname>Rossi</surname><given-names>Omar</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rondini</surname><given-names>Simona</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00122" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00122" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Babiuk</surname><given-names>Shawn</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00122"><label>1</label>GSK Vaccines Institute for Global Health (GVGH), via Fiorentina 1, 53100 Siena, Italy; <email>marika.x.pinto@gsk.com</email> (M.P.); <email>salvatore.x.durante@gsk.com</email> (S.D.); <email>martina.x.carducci@gsk.com</email> (M.C.); <email>luisa.x.massai@gsk.com</email> (L.M.); <email>renzo.x.alfini@gsk.com</email> (R.A.); <email>francesca.x.micoli@gsk.com</email> (F.M.); <email>carlo.x.giannelli@gsk.com</email> (C.G.); <email>omar.x.rossi@gsk.com</email> (O.R.)</aff><aff id="af2-vaccines-13-00122"><label>2</label>GSK, via Fiorentina 1, 53100 Siena, Italy</aff><aff id="af3-vaccines-13-00122"><label>3</label>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge CB2 0AW, UK; <email>eem55@cam.ac.uk</email> (E.M.); <email>sgb47@cam.ac.uk</email> (S.B.)</aff><aff id="af4-vaccines-13-00122"><label>4</label>Oxford University Clinical Research Unit, Patan Academy of Health Sciences, P.O. Box 26500, Kathmandu 44700, Nepal; <email>akarkey@oucru.org</email></aff><author-notes><corresp id="c1-vaccines-13-00122"><label>*</label>Correspondence: <email>simona.x.rondini@gsk.com</email></corresp><fn id="fn1-vaccines-13-00122"><label>&#x02020;</label><p>These authors contributed equally to the work.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>122</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: Typhoid and paratyphoid fevers represent a global health burden, especially in Southern Asia, exacerbated by the increase in antimicrobial resistance. While vaccines against <italic toggle="yes">Salmonella</italic> Typhi have been successfully introduced, a vaccine against <italic toggle="yes">S.</italic> Paratyphi A is not available, yet. Efforts to develop an effective vaccine targeting both <italic toggle="yes">Salmonella</italic> serovars are currently ongoing. GVGH is developing a bivalent vaccine constituted by the Vi-CRM<sub>197</sub> typhoid conjugate vaccine (TCV), and the <italic toggle="yes">Salmonella</italic> Paratyphi A O-antigen (O:2), also conjugated to the CRM<sub>197</sub> carrier protein (O:2-CRM<sub>197</sub>). In this work we have characterized a panel of <italic toggle="yes">S.</italic> Paratyphi A clinical isolates from endemic regions, differing in terms of their O:2 structural features. Methods: Rabbits were immunized with the <italic toggle="yes">S.</italic> Paratyphi A component of the vaccine candidate and the resulting sera were tested for their ability to bind and kill the isolates using flow cytometry and luminescence-based serum bactericidal assay (L-SBA). Results: The O:2-CRM<sub>197</sub> glycoconjugate induced a functional immune response in rabbits, effectively binding and killing a diverse panel of clinical isolates. The sera demonstrated bactericidal activity independent of the O:2 structural variations, including differences in O-acetylation and glucosylation levels. Additionally, the study found that the O:2-CRM<sub>197</sub> conjugate&#x02019;s adsorption to Alhydrogel did not significantly impact its immunogenicity or bactericidal efficacy. Conclusions: The O:2-CRM<sub>197</sub> component of the bivalent vaccine candidate shows promise in providing broad protection against <italic toggle="yes">S</italic>. Paratyphi A isolates, regardless of their O-antigen structural variations. The ongoing clinical studies on human sera are expected to confirm these results.</p></abstract><kwd-group><kwd><italic toggle="yes">Salmonella</italic> Paratyphi A</kwd><kwd>vaccine</kwd><kwd>O-antigen</kwd><kwd>glycoconjugate</kwd><kwd>O-acetylation</kwd><kwd>Luminescence-based serum bactericidal assay</kwd></kwd-group><funding-group><award-group><funding-source>GlaxoSmithKline Biologicals SA</funding-source></award-group><funding-statement>This work was sponsored and funded by GlaxoSmithKline Biologicals SA, which was involved in all stages of the study conduct and analysis.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00122"><title>1. Introduction</title><p>Enteric fever is a significant health issue, particularly in those countries where access to clean water and sanitation is inadequate [<xref rid="B1-vaccines-13-00122" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00122" ref-type="bibr">2</xref>]. It is caused by <italic toggle="yes">Salmonella enterica</italic> serovars Typhi and Paratyphi A, human-restricted pathogens transmitted by the fecal&#x02013;oral route. The disease primarily affects children and young adults [<xref rid="B3-vaccines-13-00122" ref-type="bibr">3</xref>]. Typhoid and paratyphoid fevers, which are clinically identical multisystemic febrile illnesses, are caused by <italic toggle="yes">Salmonella enterica</italic> serotypes Typhi (<italic toggle="yes">S.</italic> Typhi) and Paratyphi (<italic toggle="yes">S.</italic> Paratyphi A, B, and C). Enteric fever affects over 13 million individuals and results in more than 110,000 deaths annually worldwide [<xref rid="B4-vaccines-13-00122" ref-type="bibr">4</xref>].</p><p>Almost 30% of community-acquired bacterial bloodstream infections in Asia and 10% in Africa are caused by <italic toggle="yes">S</italic>. Typhi [<xref rid="B5-vaccines-13-00122" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00122" ref-type="bibr">6</xref>]. On the other hand, <italic toggle="yes">S.</italic> Paratyphi A is responsible for up to 35% of all enteric fever episodes in India and Nepal, and over 60% in China [<xref rid="B7-vaccines-13-00122" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00122" ref-type="bibr">8</xref>]. The effectiveness of classical antimicrobial therapy is being undermined by the increasing resistance of <italic toggle="yes">S.</italic> Paratyphi A strains against multiple antibiotics [<xref rid="B9-vaccines-13-00122" ref-type="bibr">9</xref>]. Patients treated with ineffective antimicrobials show a poor clinical response and a high rate of complications and deaths. This is accompanied by prolonged fecal shedding, which sustains transmission and induces secondary cases [<xref rid="B10-vaccines-13-00122" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00122" ref-type="bibr">11</xref>].</p><p>In the last few years, several Vi-conjugate vaccines have become available for the prevention of enteric fever caused by <italic toggle="yes">S.</italic> Typhi [<xref rid="B12-vaccines-13-00122" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00122" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00122" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00122" ref-type="bibr">15</xref>] and have been recommended for use in infants [<xref rid="B16-vaccines-13-00122" ref-type="bibr">16</xref>]. Despite the existence of vaccines to prevent enteric fever caused by <italic toggle="yes">S.</italic> Typhi, there is currently no licensed vaccine against <italic toggle="yes">S.</italic> Paratyphi A [<xref rid="B16-vaccines-13-00122" ref-type="bibr">16</xref>]. In areas with a high incidence of paratyphoid fever, there is a risk that even a highly effective <italic toggle="yes">S.</italic> Typhi vaccine will be insufficient to reduce the burden of enteric fever as a whole, because of the increasing detection rates of <italic toggle="yes">S.</italic> Paratyphi A and the risk of serotype replacement [<xref rid="B17-vaccines-13-00122" ref-type="bibr">17</xref>].</p><p>Therefore, several groups have started working to develop bivalent vaccines to prevent disease caused by both <italic toggle="yes">S</italic>. Typhi and <italic toggle="yes">S.</italic> Paratyphi A [<xref rid="B18-vaccines-13-00122" ref-type="bibr">18</xref>].</p><p>The GSK Vaccines Institute for Global Health, in collaboration with Biological E, has combined the licensed Vi-CRM<sub>197</sub> conjugate [<xref rid="B19-vaccines-13-00122" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00122" ref-type="bibr">20</xref>] with a new glycoconjugate constituted by <italic toggle="yes">S.</italic> Paratyphi A-specific O-antigen O:2 and CRM<sub>197</sub> [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>]. This new bivalent vaccine has recently completed a Phase 1 clinical trial in Europe (NCT05613205).</p><p>Prior to conducting clinical studies, the O:2-CRM<sub>197</sub> conjugate was demonstrated to be immunogenic in animals and able to induce serum bactericidal activity against an <italic toggle="yes">S</italic>. Paratyphi A homologous strain [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>].</p><p>The <italic toggle="yes">S</italic>. Paratyphi A O:2 repeating unit (RU) is composed of a trisaccharide backbone of rhamnose (Rha), mannose (Man), and galactose (Gal), with a terminal paratose (Par) at C-3 of Man, which confers the O:2 serospecificity. The O:2 also shows further decorations: a terminal glucose (Glc) can be linked to the C-6 of Gal, while the Rha residue can be variously substituted on C-2 and on C-3 with O-acetyl groups [<xref rid="B22-vaccines-13-00122" ref-type="bibr">22</xref>]. These O-antigen (OAg) modifications can be relevant immunological determinants [<xref rid="B23-vaccines-13-00122" ref-type="bibr">23</xref>].</p><p>In this study, we explored the OAg variations and their immunological effects on invasive clinical isolates coming from endemic regions of Nepal [<xref rid="B24-vaccines-13-00122" ref-type="bibr">24</xref>]. The O-antigens extracted from these strains were purified and fully characterized, showing differences in O:2 density, O-acetylation, and glucosylation levels.</p><p>To evaluate the relevance of these modifications, we investigated the ability of animal sera raised against O:2-CRM<sub>197</sub> glycoconjugates to bind and kill the isolates. Sera generated in rabbits by O:2-CRM<sub>197</sub> conjugates, formulated with or without adjuvant, and containing O:2 with different O-acetylation levels, were tested against these strains by flow cytometry and luminescence-based serum bactericidal assay (L-SBA) [<xref rid="B25-vaccines-13-00122" ref-type="bibr">25</xref>].</p></sec><sec id="sec2-vaccines-13-00122"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00122"><title>2.1. Bacterial Strains</title><p>The <italic toggle="yes">Salmonella</italic> Paratyphi A strains used in this study were invasive clinical isolates from Nepal and the commercial laboratory strain ATCC9150 (<xref rid="vaccines-13-00122-t001" ref-type="table">Table 1</xref>).</p><p>The Nepalese isolates were part of a larger panel of isolates from the blood cultures of patients and from chronic carriers in an urban hospital in Katmandu between 2005 and 2014 [<xref rid="B24-vaccines-13-00122" ref-type="bibr">24</xref>,<xref rid="B26-vaccines-13-00122" ref-type="bibr">26</xref>]. The entire panel of isolates was previously analyzed by whole-genome sequencing [<xref rid="B26-vaccines-13-00122" ref-type="bibr">26</xref>].</p><p>The strain identified as NVGH308 is the clinical isolate ED199, originated in 2006 from a patient with enteric fever in Katmandu [<xref rid="B27-vaccines-13-00122" ref-type="bibr">27</xref>].</p><p>All strains were stored at &#x02212;80 &#x000b0;C in 20% glycerol stocks until use.</p></sec><sec id="sec2dot2-vaccines-13-00122"><title>2.2. Conjugates Formulation</title><p>The O:2 OAg employed for the glycoconjugate synthesis was extracted from the <italic toggle="yes">S</italic>. Paratyphi A strain NVGH308 containing a &#x00394;<italic toggle="yes">tolR</italic> mutation. The OAg extracted from this modified strain has a bimodal molecular weight (MW) population (two peaks, respectively, at 16 and 100 kDa), a 60.0% O-acetylation level, and a 79.0% glucosylation level [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>].</p><p>By treating O:2 with NH<sub>4</sub>OH 1M, a completely not O-acetylated O:2 was obtained. Therefore, two different O:2-CRM<sub>197</sub> glycoconjugates were synthesized by conjugating the CRM<sub>197</sub> carrier protein with either the O-acetylated or the not O-acetylated OAg.</p><p>Formulations n. 1 and 2 (<xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref>) were prepared by adding the glycoconjugates to the following excipients: water, Tris 25 mM pH 7.2, NaCl 9 g/L, and Alhydrogel (for a final concentration of Al<sup>3+</sup> 0.75 mg/mL).</p><p>The synthesis of conjugates, the preparation of formulations 1 and 2, and their characterization are fully described in [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>].</p><p>In formulation n. 3, the glycoconjugate used was the same O-acetylated O:2-CRM<sub>197</sub> as in formulation n. 1, but in this case the Tris buffer was substituted by a phosphate buffer (pH 7.4) to prevent the adsorption of the conjugate on Alhydrogel. The adsorption of the conjugates to Alhydrogel was quantified by microBCA assay.</p><p><xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref> summarizes the main characteristics of the formulations tested in this study.</p></sec><sec id="sec2dot3-vaccines-13-00122"><title>2.3. Animal Studies</title><p>All animal studies were performed at Charles River Laboratories (France).</p><p>Groups of 8 New Zealand White rabbits (female, at least 2.5 kg in weight) were vaccinated intramuscularly with a 500 &#x003bc;L dose containing 25 &#x000b5;g of O:2-CRM<sub>197</sub> glycoconjugates on study days 0 and 28. Equal amounts of sera collected 14 days post second vaccination from each group were pooled and used in this study. In Alfini et al., individual sera from rabbits immunized with O:2-CRM<sub>197</sub>&#x02013;55.6% OAc were tested by ELISA and L-SBA against the strain NVGH308.</p><p>Body weight and temperature were monitored following vaccination for 72 h (body weight), or 24 h (temperature), or until the original values were restored in case body weight loss was &#x0003e;10% and temperature &#x0003e; 40 &#x000b0;C. Animal health conditions were monitored throughout all the studies, and no clinical signs of concern were reported.</p></sec><sec id="sec2dot4-vaccines-13-00122"><title>2.4. Ethics and 3R Statement</title><p>All animal experiments were performed in accordance with the European Directive for the Use of Animals for Scientific Purposes 2010/63 and GSK policy on the Care, Welfare and Treatment of Animals. GSK is committed to the replacement, reduction, and refinement of animal studies (3Rs). Non animal models and alternative technologies are part of our strategy and are employed where possible. When animals are required, the application of robust study design principles and peer review minimizes animal use, reduces harm, and improves the benefit to studies.</p></sec><sec id="sec2dot5-vaccines-13-00122"><title>2.5. O-Antigen Extraction and Characterization</title><p>O-antigens were extracted from the bacterial strains listed in <xref rid="vaccines-13-00122-t001" ref-type="table">Table 1</xref> following a procedure previously reported [<xref rid="B28-vaccines-13-00122" ref-type="bibr">28</xref>] with few modifications (<xref rid="vaccines-13-00122-sch001" ref-type="fig">Scheme 1</xref>).</p><p>A daytime culture was started from frozen stock in 5 mL of Luria&#x02013;Bertani (LB) for 6&#x02013;8 h at 37 &#x000b0;C and 180 rpm prior to being transferred to a 50 mL overnight culture (16&#x02013;18 h) in LB at 37 &#x000b0;C and 180 rpm. Afterwards, the bacterial culture was centrifuged (5000 rcf, 30 min), the supernatant discarded, and the pellet was resuspended in acetic acid 2% (<italic toggle="yes">v/v</italic>) and incubated at 100 &#x000b0;C for 5 h. Through a second centrifugation step (5000 rcf, 45 min), the OAg solution was recovered and separated from the pellet that contains lipid A, membrane debris, and proteins. After the hydrolysis, the pH was increased to 6 by adding 28% NH<sub>4</sub>OH. The solution was then ultrafiltered with Amicon Ultra Centrifugal Filter 10 kDa (Merck, Darmstadt, Germany) to remove the lower molecular mass impurities, first against NaCl 1M (3 cycles, 1895 rcf, 20 min) and then against water (3 cycles, 1895 rcf, 20 min). The OAg was then quantified by High-Performance Anion-Exchange Chromatography coupled to a Pulsed Amperometric Detector (HPAEC-PAD) [<xref rid="B29-vaccines-13-00122" ref-type="bibr">29</xref>].</p><p>The ultrafiltered solution was then further purified by adding citrate buffer pH 2.7 (final concentration 20 mM) to precipitate protein impurities. The supernatant was further purified by adding Na<sub>2</sub>HPO<sub>4</sub>, EtOH, and CaCl<sub>2</sub> to have 18 mM NaH<sub>2</sub>PO<sub>4</sub>, 24% EtOH (<italic toggle="yes">v/v</italic>), and 200 mM CaCl<sub>2</sub> in the final mixture to co-precipitate nucleic acid. The solution containing OAg was finally ultrafiltered in Amicon Ultra 10 kDa vs. NaCl 1M (3 cycles, 1895 rcf, 20 min) and vs. water (3 cycles, 1895 rcf, 20 min). The resulting solution was used to calculate the OAg molecular weight with GPC using a Dextrans calibration curve, as previously reported [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>], and the O-acetylation level.</p><p>The O-acetyl ester content was determined by performing a modified microplate procedure of the Hestrin assay [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>].</p><p>Finally, the lipid A core was removed by ultrafiltration using Amicon Ultra with a higher cut-off (30 kDa) and the OAg glucose content was estimated by HPAEC-PAD analysis and reported as the molar ratio to mannose.</p></sec><sec id="sec2dot6-vaccines-13-00122"><title>2.6. Flow Cytometry Binding Assay</title><p>Overnight cultures of strains, listed in <xref rid="vaccines-13-00122-t001" ref-type="table">Table 1</xref>, were started from frozen stocks and then diluted in 7 mL of warm LB medium from an optical density at OD<sub>600nm</sub> =0.05 and incubated at 37 &#x000b0;C with 180 rpm agitation in an orbital shaker until they reached an OD<sub>600nm</sub> between 0.18 and 0.25. Then, 1 mL of working culture was pelleted at 12,000&#x000d7; <italic toggle="yes">g</italic> for 10 min and resuspended in 1 mL PBS + 1% BSA buffer. An amount ot 50 mL of bacteria suspension was then added to a 96-well plate (Costar), washed with 100 mL PBS + 1% BSA, centrifuged at 4000&#x000d7; <italic toggle="yes">g</italic> for 10 min, and the supernatant was discarded. The bacteria in the pellet were fixed by resuspending each well in 50 &#x000b5;L Cytofix (BD) solution. After incubation for 30 min at 4 &#x000b0;C, the plate was centrifuged at 4000&#x000d7; <italic toggle="yes">g</italic> for 10 min, the supernatants were discarded, and the bacterial pellets were washed twice with PBS + 1% BSA buffer. Then, the bacteria pellets were incubated with primary antibodies (pooled sera from rabbits obtained by immunizing with the constructs reported in <xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref> and diluted to 1:500 in PBS + 1% BSA; pre-immune sera diluted to 1:500 in PBS + 1% BSA were used as negative controls) for 30 min under orbital shaking at 750 rpm at 25 &#x000b0;C. The bacterial pellet was washed twice with 100 mL PBS + 1% BSA buffer and then incubated with 50 mL of anti-rabbit IgG-PE (BD) for 30 min with shaking at 750 rpm at 25 &#x000b0;C. The bacterial pellets were washed twice with 100 &#x000b5;L PBS + 1% BSA buffer and resuspended in 150 mL PBS + 1% BSA buffer. The plate was acquired with BD Accuri flow cytometer (BD, Franklin Lakes, U.S.) with CSampler Plus. A gating was first set in the forward (FSC) and side scatter (SSC). The acquisition was set to 10,000 bacterial events inside the bacterial gating, with a slow acquisition speed, and a 4500-threshold set for FSC-H. The samples were analyzed in FlowJo. Bacterial cells were gated manually leaving out agglutinated bacteria or clumps and the geometric mean of fluorescence intensity (MFI) was extrapolated.</p></sec><sec id="sec2dot7-vaccines-13-00122"><title>2.7. Luminescence-Based Serum Bactericidal Assay</title><p>The luminescence-based serum bactericidal assay (L-SBA) was performed as previously described [<xref rid="B25-vaccines-13-00122" ref-type="bibr">25</xref>]. Briefly, a daytime culture was started at OD<sub>600nm</sub> = 0.05 from an overnight culture, until it reached an OD<sub>600nm</sub> between 0.22 and 0.25. The bacteria were then diluted at 1:600 and sera were heat-inactivated (HI) at 56 &#x000b0;C for 30 min to remove endogenous complement activity.</p><p>To estimate the signal released from the initial concentration of bacteria, the luminescence at T0 was measured. The reaction mixtures were prepared in a final volume of 100 &#x000b5;L, containing 10 &#x000b5;L of the bacterial cells diluted, 25 &#x000b5;L of baby rabbit complement (Cederlane) as an external source of complement, and 25 &#x000b5;L of HI serum. The plates were incubated for 3 h at 37 &#x000b0;C and then centrifuged at 25 &#x000b0;C for 10 min at 4000&#x000d7; <italic toggle="yes">g</italic>. The supernatant was discarded to remove the ATP derived from dead bacteria and L-SBA reagents, and the remaining live bacterial pellets were resuspended in 100 &#x000b5;L PBS. The luminescent signal was detected by testing the bacterial pellet mixed 1:1 with BacTiter-Glo Reagent (Promega, Madison, U.S.) using a Synergy luminometer (Biotek, Winooski, U.S). Bactericidal serum titers were calculated by fitting a four-parameter logistic curve to the raw luminescence signal in function to the different Log sera dilutions by GraphPad Prism 9.3.1. Bactericidal titers were represented by the reciprocal serum dilution necessary to obtain 50% bacterial growth inhibition.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00122"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00122"><title>3.1. S. Paratyphi A Isolates Express OAg with Different Levels of O-Acetylation, Glucosylation, and Molecular Weight</title><p>O-antigens were isolated from the <italic toggle="yes">S.</italic> Paratyphi A strains, and fully characterized in terms of polysaccharide chain length, quantity, percentage of O-acetyl groups, and Glc content (see <xref rid="vaccines-13-00122-t001" ref-type="table">Table 1</xref>).</p><p>The bacteria were grown in the same conditions and reached a similar OD600 (range from 3.2 to 4.2). Despite that, the OAg amount produced by the strains was different, ranging from 44 &#x000b5;g of polysaccharide per OD for the laboratory strain ATCC9150 to 396 &#x000b5;g of polysaccharide per OD for the clinical isolate 02TY046.</p><p>Most isolates presented OAg populations at two different molecular weights: a high molecular weight population (HMW) at around 90 kDa, and a medium molecular weight (MMW) population at around 10 kDa, whose peak is not completely separated from the peak relative to the core, or the core plus a few RUs only at around 2 kDa (<xref rid="vaccines-13-00122-f001" ref-type="fig">Figure 1</xref>). The OAg extracted from isolate 02Y004 shows the peak corresponding to the HMW population slightly above the average, at 111.3 kDa, while isolates 02TY046 and NVGH308 did not present the MMW peak (differences with the strain NVGH308 &#x00394;<italic toggle="yes">tolR</italic> used for the glycoconjugate synthesis are probably related to the different growth conditions).</p><p>None of the strains presented completely the O-acetylated O:2 and only strain ED766 presented OAg with 100% O-acetylation. All other isolates showed a range of O-acetylation levels, with the laboratory strain ATCC9150 characterized by the lowest O-acetylation level (17%) of the panel.</p><p>Glucosylation levels, calculated on the OAg hydrolyzed after the core&#x02019;s removal, were in the range of 49 to 95% (<xref rid="vaccines-13-00122-f002" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec3dot2-vaccines-13-00122"><title>3.2. Sera Raised Against O:2 CRM<sub>197</sub> Conjugates Are Able to Bind and Kill Clinical Isolates with Different OAg Characteristics</title><p>Rabbit sera obtained after immunization with 55.6% O-acetylated O:2-CRM<sub>197</sub> vaccine candidate (<xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref>, formulation n. 1) were able to bind all clinical isolates by flow cytometry (<xref rid="vaccines-13-00122-f003" ref-type="fig">Figure 3</xref>).</p><p>Complement is a key factor in each L-SBA assay and the appropriateness of the source and amount must be evaluated; therefore we first examined the susceptibility of bacterial strains to complement. All the strains, independently of their OAg characteristics, presented analogous sensitivity to non-specific complement killing and were tested by L-SBA using the same conditions and same amount of exogenous complement. Rabbit sera killed all tested clinical isolates (<xref rid="vaccines-13-00122-f004" ref-type="fig">Figure 4</xref>), regardless of their different OAg characteristics.</p><p>To verify if the O:2-CRM<sub>197</sub> O-acetylation level plays a role in the bactericidal activity against the differently O-acetylated isolates, we tested sera after immunization with the not O-acetylated conjugate (<xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref>, formulation n. 2). The sera were still able to bind (<xref rid="vaccines-13-00122-f003" ref-type="fig">Figure 3</xref>) and kill (<xref rid="vaccines-13-00122-f004" ref-type="fig">Figure 4</xref>) all the isolates, regardless their O-acetylation levels.</p><p>Also, we wanted to investigate the impact of adsorption on the Alhydrogel of the glycoconjugates. Comparing sera coming from immunizations with either adsorbed or minimally adsorbed O:2-CRM<sub>197</sub> (<xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref>, formulations n. 1 and 3), we found a similar binding and bactericidal activity against the tested strains (<xref rid="vaccines-13-00122-f003" ref-type="fig">Figure 3</xref> and <xref rid="vaccines-13-00122-f004" ref-type="fig">Figure 4</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00122"><title>4. Discussion</title><p>Typhoid and paratyphoid fever still represent a major global health problem, particularly in children in South and South-East Asia. Despite the successful introduction of vaccines against <italic toggle="yes">Salmonella</italic> Typhi, there is still no vaccine against <italic toggle="yes">S.</italic> Paratyphi A, and <italic toggle="yes">S.</italic> Paratyphi A-containing vaccines have been identified as a strategic priority by the WHO [<xref rid="B30-vaccines-13-00122" ref-type="bibr">30</xref>].</p><p>We have previously shown that animal sera obtained after O:2-CRM<sub>197</sub> immunization can effectively kill an <italic toggle="yes">S</italic>. Paratyphi A strain whose OAg was used to generate the O:2-CRM<sub>197</sub> candidate vaccine [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>]. However, <italic toggle="yes">S.</italic> Paratyphi A strains may have O-antigens with different levels of O-acetylation, glucosylation, and relative expression of OAg.</p><p>Therefore, we tested a panel of endemic strains to assess possible differences in their OAg characteristics, and to evaluate if our <italic toggle="yes">S.</italic> Paratyphi A vaccine candidate could generate an antibody response able to neutralize them. A vaccine effective across multiple strains would minimize the risk of encountering strains able to escape its potential coverage [<xref rid="B31-vaccines-13-00122" ref-type="bibr">31</xref>].</p><p>Even though some work has been done to study the genetic variation in <italic toggle="yes">S</italic>. Paratyphi A isolates [<xref rid="B32-vaccines-13-00122" ref-type="bibr">32</xref>] and their population structure in specific endemic regions [<xref rid="B26-vaccines-13-00122" ref-type="bibr">26</xref>], very little is known about variation in OAg features among clinical isolates. Genomic studies have found a relative homogeneous population structure, where genotype replacement may be driven by reduced susceptibility to antibiotics (i.e., fluoroquinolones) and by possible changes in virulence factors, providing an increased fitness.</p><p>A more recent study from the University of Cambridge provided a deeper understanding of the phenotypic variations in a collection of <italic toggle="yes">S</italic>. Paratyphi A OAg isolates from Nepal, identifying two specific variations in the LPS, &#x0201c;typical&#x0201d; and &#x0201c;variant&#x0201d;, that could be related to some structural modifications of the OAg [<xref rid="B24-vaccines-13-00122" ref-type="bibr">24</xref>].</p><p>In this report, for the first time, we chemically characterized the OAg from a representative panel of clinical isolates, and included the laboratory strain ATCC9150, whose genome was the first to be sequenced in 2004 [<xref rid="B33-vaccines-13-00122" ref-type="bibr">33</xref>]. Excluding the less relevant laboratory strain, we found that, in the same growth conditions, <italic toggle="yes">S</italic>. Paratyphi A isolates presented an amount of OAg/OD production with a 6-fold difference between the highest and the lowest producer; OAc levels with a 3-fold difference between the highest and the lowest O-acetylated strain (mean around 73% O-acetylation); and glucosylation levels with a 2-fold difference between the highest and the lowest glycosylated strain (mean around 72%). Most strains presented OAg with a bimodal MW distribution at medium and high MW.</p><p>This variation in OAg characteristics is of high interest and, for other <italic toggle="yes">S. enterica</italic> serovars such as <italic toggle="yes">S</italic>. Typhimurium [<xref rid="B34-vaccines-13-00122" ref-type="bibr">34</xref>], may be indicative of different selective pressures.</p><p>The OAg moiety of lipopolysaccharides is considered a possible target of protective immune responses, and OAg-based vaccine candidates are in development for additional <italic toggle="yes">Salmonella</italic> serovars like Typhimurium and Enteritidis [<xref rid="B35-vaccines-13-00122" ref-type="bibr">35</xref>], along with other <italic toggle="yes">Enterobacteriaceae</italic> pathogens like <italic toggle="yes">Shigella</italic> spp [<xref rid="B36-vaccines-13-00122" ref-type="bibr">36</xref>], <italic toggle="yes">K. pneumoniae</italic>, etc. [<xref rid="B37-vaccines-13-00122" ref-type="bibr">37</xref>]. For <italic toggle="yes">Salmonella</italic> serovars, OAg characteristics such as molecular size and O-acetylation levels and position have been shown to play an important role in virulence [<xref rid="B38-vaccines-13-00122" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00122" ref-type="bibr">39</xref>] and in the ability of a OAg-based candidate to induce immunogenic responses in animals [<xref rid="B40-vaccines-13-00122" ref-type="bibr">40</xref>]. More specifically, O-acetyls were confirmed to be immunodominant epitopes of <italic toggle="yes">S</italic>. Typhimurium OAg [<xref rid="B41-vaccines-13-00122" ref-type="bibr">41</xref>] and, also for <italic toggle="yes">S</italic>. Typhi, O-acetylation was found to be a critical determinant of immunogenicity of the Vi polysaccharide antigen [<xref rid="B42-vaccines-13-00122" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00122" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-13-00122" ref-type="bibr">44</xref>].</p><p>In the case of <italic toggle="yes">S</italic>. Paratyphi A, OAg MW may impact the immunogenicity of O:2-conjugates: Alfini et al. [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>] showed higher immune responses in mice (but not in rabbits) for O:2-CRM<sub>197</sub> with conjugates containing O:2 at a low MW, while Konadu et al. showed the opposite for a different O:2-TT conjugate [<xref rid="B23-vaccines-13-00122" ref-type="bibr">23</xref>]. In addition, O-acetylation may be an important determinant of functional humoral response and both Alfini et al. and Konadu et al. showed the enhanced immunogenicity and bactericidal activity of mouse sera from conjugates containing O-acetylated OAg. Clearly, the ability of OAg features to influence the response to a glycoconjugate should be evaluated concomitantly with multiple other parameters, and, most importantly, in relation to the animal species used.</p><p>In this report, using rabbit as animal model, we found that sera from de O-acetylated O:2-CRM<sub>197</sub> conjugates were as able to bind and kill the <italic toggle="yes">S</italic>. Paratyphi A strains as sera from O-acetylated conjugates. This finding suggests a non-critical role in the bactericidal activity of rabbit antibodies against O-acetylated epitopes and it differs from what had previously been found in mice [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>].</p><p>Similarly, adsorption to Alhydrogel did not seem to contribute to enhance the conjugates immunogenicity.</p><p>That said, we observed a trend for the higher binding and increased bactericidal activity of sera raised by minimally adsorbed and not O-acetylated OAg-conjugates. The significance of this finding is currently unknown, and it is similarly unknown what animal species can best predict the response in humans.</p><p>Clearly, most relevant results will come from the recently completed Phase 1 clinical study, where a bivalent conjugate vaccine containing TCV and O:2-CRM<sub>197</sub>, adsorbed or not to Alhydrogel, has been administered to healthy adults.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00122"><title>5. Conclusions</title><p>In conclusion, the results of this work show that our O:2-CRM<sub>197</sub> conjugate could theoretically protect against multiple clinical isolates, regardless of their OAg characteristics, thus supporting the further development of the bivalent vaccine against Typhi and Paratyphi A. These results will be confirmed with the most relevant clinical sera, as soon as available.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.P., S.D., C.G., O.R. and S.R.; formal analysis, M.P., S.D., M.C., L.M., R.A., F.M., C.G., O.R. and S.R.; investigation, M.P., S.D., M.C., L.M. and R.A.; resources, E.M., A.K. and S.B., methodology, M.P., S.D., C.G., O.R. and S.R.; supervision, F.M., C.G., O.R. and S.R.; writing&#x02014;original draft preparation, M.P., S.D., M.C., C.G., O.R. and S.R.; writing&#x02014;review and editing, M.P., S.D., M.C., L.M., R.A., E.M., A.K., S.B., F.M., C.G., O.R. and S.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All animal sera used in this study were derived from immunization experiments performed at the Charles River Laboratories (France). Animal studies were reviewed by the ethic committee Animal Welfare Body GSK Siena (Project code: APAFIS #2016061011167092, date of approval: 11 September 2018) and carried out in compliance with animal welfare standards according to European Directive 63/2010, local legislation, and the GSK policy on the Care, Welfare and Treatment of Animals.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author(s).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>This work was performed at the request of and sponsored by GlaxoSmithKline Biologicals SA, who was involved in all stages of the study and analysis. M.P., S.D., M.C., L.M., R.A., F.M., C.G., O.R. and S.R. are employees of the GSK group of companies. GSK Vaccines Institute for Global Health srl is an affiliate of GlaxoSmithKline Biologicals SA.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00122"><label>1.</label><element-citation publication-type="journal"><article-title>The global burden of typhoid and paratyphoid fevers: A systematic analysis for the Global Burden of Disease Study 2017</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30685-6</pub-id><pub-id pub-id-type="pmid">30792131</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00122"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crump</surname><given-names>J.A.</given-names></name>
<name><surname>Sj&#x000f6;lund-Karlsson</surname><given-names>M.</given-names></name>
<name><surname>Gordon</surname><given-names>M.A.</given-names></name>
<name><surname>Parry</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections</article-title><source>Clin. Microbiol. Rev.</source><year>2015</year><volume>28</volume><fpage>901</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1128/CMR.00002-15</pub-id><pub-id pub-id-type="pmid">26180063</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00122"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Browne</surname><given-names>A.J.</given-names></name>
<name><surname>Kashef Hamadani</surname><given-names>B.H.</given-names></name>
<name><surname>Kumaran</surname><given-names>E.A.P.</given-names></name>
<name><surname>Rao</surname><given-names>P.</given-names></name>
<name><surname>Longbottom</surname><given-names>J.</given-names></name>
<name><surname>Harriss</surname><given-names>E.</given-names></name>
<name><surname>Moore</surname><given-names>C.E.</given-names></name>
<name><surname>Dunachie</surname><given-names>S.</given-names></name>
<name><surname>Basnyat</surname><given-names>B.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Drug-resistant enteric fever worldwide, 1990 to 2018: A systematic review and meta-analysis</article-title><source>BMC Med.</source><year>2020</year><volume>18</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-019-1443-1</pub-id><pub-id pub-id-type="pmid">31898501</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00122"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bhandari</surname><given-names>J.</given-names></name>
<name><surname>Thada</surname><given-names>P.K.</given-names></name>
<name><surname>Hashmi</surname><given-names>M.F.</given-names></name>
<name><surname>DeVos</surname><given-names>E.</given-names></name>
</person-group><article-title>Typhoid Fever</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing LLC.</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B5-vaccines-13-00122"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deen</surname><given-names>J.</given-names></name>
<name><surname>von Seidlein</surname><given-names>L.</given-names></name>
<name><surname>Andersen</surname><given-names>F.</given-names></name>
<name><surname>Elle</surname><given-names>N.</given-names></name>
<name><surname>White</surname><given-names>N.J.</given-names></name>
<name><surname>Lubell</surname><given-names>Y.</given-names></name>
</person-group><article-title>Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: A systematic review</article-title><source>Lancet Infect. Dis.</source><year>2012</year><volume>12</volume><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(12)70028-2</pub-id><pub-id pub-id-type="pmid">22632186</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00122"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pieters</surname><given-names>Z.</given-names></name>
<name><surname>Saad</surname><given-names>N.J.</given-names></name>
<name><surname>Antill&#x000f3;n</surname><given-names>M.</given-names></name>
<name><surname>Pitzer</surname><given-names>V.E.</given-names></name>
<name><surname>Bilcke</surname><given-names>J.</given-names></name>
</person-group><article-title>Case Fatality Rate of Enteric Fever in Endemic Countries: A Systematic Review and Meta-analysis</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>67</volume><fpage>628</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy190</pub-id><pub-id pub-id-type="pmid">29522159</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00122"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maskey</surname><given-names>A.P.</given-names></name>
<name><surname>Day</surname><given-names>J.N.</given-names></name>
<name><surname>Phung</surname><given-names>Q.T.</given-names></name>
<name><surname>Thwaites</surname><given-names>G.E.</given-names></name>
<name><surname>Campbell</surname><given-names>J.I.</given-names></name>
<name><surname>Zimmerman</surname><given-names>M.</given-names></name>
<name><surname>Farrar</surname><given-names>J.J.</given-names></name>
<name><surname>Basnyat</surname><given-names>B.</given-names></name>
</person-group><article-title>Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal</article-title><source>Clin. Infect. Dis.</source><year>2006</year><volume>42</volume><fpage>1247</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1086/503033</pub-id><pub-id pub-id-type="pmid">16586383</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00122"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ochiai</surname><given-names>R.L.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>von Seidlein</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Bhutta</surname><given-names>Z.A.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>S.K.</given-names></name>
<name><surname>Agtini</surname><given-names>M.</given-names></name>
<name><surname>Deen</surname><given-names>J.L.</given-names></name>
<name><surname>Wain</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>D.R.</given-names></name>
<etal/>
</person-group><article-title>Salmonella paratyphi A rates, Asia</article-title><source>Emerg. Infect. Dis.</source><year>2005</year><volume>11</volume><fpage>1764</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.3201/eid1111.050168</pub-id><pub-id pub-id-type="pmid">16318734</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00122"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fangtham</surname><given-names>M.</given-names></name>
<name><surname>Wilde</surname><given-names>H.</given-names></name>
</person-group><article-title>Emergence of Salmonella paratyphi A as a major cause of enteric fever: Need for early detection, preventive measures, and effective vaccines</article-title><source>J. Travel Med.</source><year>2008</year><volume>15</volume><fpage>344</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1111/j.1708-8305.2008.00237.x</pub-id><pub-id pub-id-type="pmid">19006508</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00122"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parry</surname><given-names>C.M.</given-names></name>
<name><surname>Vinh</surname><given-names>H.</given-names></name>
<name><surname>Chinh</surname><given-names>N.T.</given-names></name>
<name><surname>Wain</surname><given-names>J.</given-names></name>
<name><surname>Campbell</surname><given-names>J.I.</given-names></name>
<name><surname>Hien</surname><given-names>T.T.</given-names></name>
<name><surname>Farrar</surname><given-names>J.J.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
</person-group><article-title>The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy</article-title><source>PLoS Neglected Trop. Dis.</source><year>2011</year><volume>5</volume><elocation-id>e1163</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001163</pub-id><pub-id pub-id-type="pmid">21713025</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00122"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walia</surname><given-names>M.</given-names></name>
<name><surname>Gaind</surname><given-names>R.</given-names></name>
<name><surname>Mehta</surname><given-names>R.</given-names></name>
<name><surname>Paul</surname><given-names>P.</given-names></name>
<name><surname>Aggarwal</surname><given-names>P.</given-names></name>
<name><surname>Kalaivani</surname><given-names>M.</given-names></name>
</person-group><article-title>Current perspectives of enteric fever: A hospital-based study from India</article-title><source>Ann. Trop. Paediatr.</source><year>2005</year><volume>25</volume><fpage>161</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1179/146532805X58085</pub-id><pub-id pub-id-type="pmid">16156980</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00122"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burki</surname><given-names>T.</given-names></name>
</person-group><article-title>Typhoid conjugate vaccine gets WHO prequalification</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>258</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30087-2</pub-id><pub-id pub-id-type="pmid">29485093</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00122"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>P.D.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Meiring</surname><given-names>J.E.</given-names></name>
<name><surname>Chasweka</surname><given-names>N.</given-names></name>
<name><surname>Patel</surname><given-names>P.</given-names></name>
<name><surname>Misiri</surname><given-names>T.</given-names></name>
<name><surname>Mwakiseghile</surname><given-names>F.</given-names></name>
<name><surname>Wachepa</surname><given-names>R.</given-names></name>
<name><surname>Banda</surname><given-names>H.C.</given-names></name>
<name><surname>Shumba</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of typhoid conjugate vaccine: Final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02031-7</pub-id><pub-id pub-id-type="pmid">38281499</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00122"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steele</surname><given-names>A.D.</given-names></name>
<name><surname>Carey</surname><given-names>M.E.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
<name><surname>Ma</surname><given-names>L.F.</given-names></name>
<name><surname>Diaz</surname><given-names>Z.</given-names></name>
<name><surname>Zaidi</surname><given-names>A.K.M.</given-names></name>
</person-group><article-title>Typhoid Conjugate Vaccines and Enteric Fever Control: Where to Next?</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><issue>(Suppl. S2)</issue><fpage>S185</fpage><lpage>S190</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa343</pub-id><pub-id pub-id-type="pmid">32725223</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00122"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gibani</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>435</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(21)00560-0</pub-id><pub-id pub-id-type="pmid">34942089</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00122"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darton</surname><given-names>T.C.</given-names></name>
<name><surname>Meiring</surname><given-names>J.E.</given-names></name>
<name><surname>Tonks</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>M.A.</given-names></name>
<name><surname>Khanam</surname><given-names>F.</given-names></name>
<name><surname>Shakya</surname><given-names>M.</given-names></name>
<name><surname>Thindwa</surname><given-names>D.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Basnyat</surname><given-names>B.</given-names></name>
<name><surname>Clemens</surname><given-names>J.D.</given-names></name>
<etal/>
</person-group><article-title>The STRATAA study protocol: A programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys</article-title><source>BMJ Open</source><year>2017</year><volume>7</volume><fpage>e016283</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2017-016283</pub-id><pub-id pub-id-type="pmid">28674145</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00122"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>B.Q.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.Y.</given-names></name>
<name><surname>Gong</surname><given-names>J.</given-names></name>
<name><surname>von Seidlein</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>M.L.</given-names></name>
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Liao</surname><given-names>H.Z.</given-names></name>
<name><surname>Ochiai</surname><given-names>R.L.</given-names></name>
<name><surname>Xu</surname><given-names>Z.Y.</given-names></name>
<etal/>
</person-group><article-title>Trends and disease burden of enteric fever in Guangxi province, China, 1994&#x02013;2004</article-title><source>Bull. World Health Organ.</source><year>2010</year><volume>88</volume><fpage>689</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.2471/BLT.09.069310</pub-id><pub-id pub-id-type="pmid">20865074</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00122"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
<name><surname>Stanaway</surname><given-names>J.</given-names></name>
<name><surname>Grow</surname><given-names>S.</given-names></name>
<name><surname>Vannice</surname><given-names>K.</given-names></name>
<name><surname>Steele</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Salmonella Combination Vaccines: Moving Beyond Typhoid</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><issue>(Suppl. S1)</issue><fpage>S58</fpage><lpage>S66</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofad041</pub-id><pub-id pub-id-type="pmid">37274529</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00122"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Bjarnarson</surname><given-names>S.P.</given-names></name>
<name><surname>Arcuri</surname><given-names>M.</given-names></name>
<name><surname>Aradottir Pind</surname><given-names>A.A.</given-names></name>
<name><surname>Magnusdottir</surname><given-names>G.J.</given-names></name>
<name><surname>Necchi</surname><given-names>F.</given-names></name>
<name><surname>Di Benedetto</surname><given-names>R.</given-names></name>
<name><surname>Carducci</surname><given-names>M.</given-names></name>
<name><surname>Schiavo</surname><given-names>F.</given-names></name>
<name><surname>Giannelli</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM(197) conjugate vaccine</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>24443</fpage><lpage>24449</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005857117</pub-id><pub-id pub-id-type="pmid">32900928</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00122"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arcuri</surname><given-names>M.</given-names></name>
<name><surname>Di Benedetto</surname><given-names>R.</given-names></name>
<name><surname>Cunningham</surname><given-names>A.F.</given-names></name>
<name><surname>Saul</surname><given-names>A.</given-names></name>
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
</person-group><article-title>The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0189100</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0189100</pub-id><pub-id pub-id-type="pmid">29287062</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00122"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alfini</surname><given-names>R.</given-names></name>
<name><surname>Carducci</surname><given-names>M.</given-names></name>
<name><surname>Massai</surname><given-names>L.</given-names></name>
<name><surname>De Simone</surname><given-names>D.</given-names></name>
<name><surname>Mariti</surname><given-names>M.</given-names></name>
<name><surname>Rossi</surname><given-names>O.</given-names></name>
<name><surname>Rondini</surname><given-names>S.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Giannelli</surname><given-names>C.</given-names></name>
</person-group><article-title>Design of a Glycoconjugate Vaccine Against Salmonella Paratyphi A</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>1272</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12111272</pub-id><pub-id pub-id-type="pmid">39591175</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00122"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ravenscroft</surname><given-names>N.</given-names></name>
<name><surname>Cescutti</surname><given-names>P.</given-names></name>
<name><surname>Gavini</surname><given-names>M.</given-names></name>
<name><surname>Stefanetti</surname><given-names>G.</given-names></name>
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
<name><surname>Martin</surname><given-names>L.B.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
</person-group><article-title>Structural analysis of the O-acetylated O-polysaccharide isolated from Salmonella paratyphi A and used for vaccine preparation</article-title><source>Carbohydr. Res.</source><year>2015</year><volume>404</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.carres.2014.12.002</pub-id><pub-id pub-id-type="pmid">25665787</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00122"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Konadu</surname><given-names>E.</given-names></name>
<name><surname>Shiloach</surname><given-names>J.</given-names></name>
<name><surname>Bryla</surname><given-names>D.A.</given-names></name>
<name><surname>Robbins</surname><given-names>J.B.</given-names></name>
<name><surname>Szu</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls</article-title><source>Infect. Immun.</source><year>1996</year><volume>64</volume><fpage>2709</fpage><lpage>2715</lpage><pub-id pub-id-type="doi">10.1128/iai.64.7.2709-2715.1996</pub-id><pub-id pub-id-type="pmid">8698499</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00122"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mylona</surname><given-names>E.</given-names></name>
<name><surname>Pereira-Dias</surname><given-names>J.</given-names></name>
<name><surname>Keane</surname><given-names>J.A.</given-names></name>
<name><surname>Karkey</surname><given-names>A.</given-names></name>
<name><surname>Dongol</surname><given-names>S.</given-names></name>
<name><surname>Khokhar</surname><given-names>F.</given-names></name>
<name><surname>Tran</surname><given-names>T.A.</given-names></name>
<name><surname>Cormie</surname><given-names>C.</given-names></name>
<name><surname>Higginson</surname><given-names>E.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
</person-group><article-title>Phenotypic variation in the lipopolysaccharide O-antigen of Salmonella Paratyphi A and implications for vaccine development</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>126404</fpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.126404</pub-id><pub-id pub-id-type="pmid">39383552</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00122"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Necchi</surname><given-names>F.</given-names></name>
<name><surname>Saul</surname><given-names>A.</given-names></name>
<name><surname>Rondini</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0172163</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0172163</pub-id><pub-id pub-id-type="pmid">28192483</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00122"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mylona</surname><given-names>E.</given-names></name>
<name><surname>Pham Thanh</surname><given-names>D.</given-names></name>
<name><surname>Keane</surname><given-names>J.A.</given-names></name>
<name><surname>Dongol</surname><given-names>S.</given-names></name>
<name><surname>Basnyat</surname><given-names>B.</given-names></name>
<name><surname>Dolecek</surname><given-names>C.</given-names></name>
<name><surname>Voong Vinh</surname><given-names>P.</given-names></name>
<name><surname>Tran Vu Thieu</surname><given-names>N.</given-names></name>
<name><surname>Nguyen Thi Nguyen</surname><given-names>T.</given-names></name>
<name><surname>Karkey</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>A retrospective investigation of the population structure and geospatial distribution of Salmonella Paratyphi A in Kathmandu, Nepal</article-title><source>PLoS Neglected Trop. Dis.</source><year>2024</year><volume>18</volume><elocation-id>e0011864</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0011864</pub-id><pub-id pub-id-type="pmid">38889189</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00122"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobinson</surname><given-names>H.C.</given-names></name>
<name><surname>Gibani</surname><given-names>M.M.</given-names></name>
<name><surname>Jones</surname><given-names>C.</given-names></name>
<name><surname>Thomaides-Brears</surname><given-names>H.B.</given-names></name>
<name><surname>Voysey</surname><given-names>M.</given-names></name>
<name><surname>Darton</surname><given-names>T.C.</given-names></name>
<name><surname>Waddington</surname><given-names>C.S.</given-names></name>
<name><surname>Campbell</surname><given-names>D.</given-names></name>
<name><surname>Milligan</surname><given-names>I.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1093/cid/cix042</pub-id><pub-id pub-id-type="pmid">28158395</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00122"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Francesca Micoli</surname><given-names>C.G.</given-names></name>
<name><surname>Di Benedetto</surname><given-names>R.</given-names></name>
</person-group><article-title>Vaccine Delivery Technology</article-title><source>Methods in Molecular Biology</source><person-group person-group-type="editor">
<name><surname>Walker</surname><given-names>J.M.</given-names></name>
</person-group><publisher-name>Humana</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2021</year><fpage>590</fpage></element-citation></ref><ref id="B29-vaccines-13-00122"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Alfini</surname><given-names>R.</given-names></name>
<name><surname>Giannelli</surname><given-names>C.</given-names></name>
</person-group><article-title>Methods for Assessment of OMV/GMMA Quality and Stability</article-title><source>Methods Mol. Biol.</source><year>2022</year><volume>2414</volume><fpage>227</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">34784041</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00122"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>L.B.</given-names></name>
<name><surname>Khanam</surname><given-names>F.</given-names></name>
<name><surname>Qadri</surname><given-names>F.</given-names></name>
<name><surname>Khalil</surname><given-names>I.</given-names></name>
<name><surname>Sikorski</surname><given-names>M.J.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
</person-group><article-title>Vaccine value profile for Salmonella enterica serovar Paratyphi A</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><issue>(Suppl. S2)</issue><fpage>S114</fpage><lpage>S133</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.01.054</pub-id><pub-id pub-id-type="pmid">37951691</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00122"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooda</surname><given-names>Y.</given-names></name>
<name><surname>Tanmoy</surname><given-names>A.M.</given-names></name>
<name><surname>Saha</surname><given-names>S.K.</given-names></name>
<name><surname>Saha</surname><given-names>S.</given-names></name>
</person-group><article-title>Genomic Surveillance of Salmonella Paratyphi A: Neglected No More?</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><issue>(Suppl. S1)</issue><fpage>S53</fpage><lpage>S57</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofad077</pub-id><pub-id pub-id-type="pmid">37274527</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00122"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>S.I.A.</given-names></name>
<name><surname>Nguyen</surname><given-names>T.N.T.</given-names></name>
<name><surname>Khanam</surname><given-names>F.</given-names></name>
<name><surname>Thomson</surname><given-names>N.R.</given-names></name>
<name><surname>Dyson</surname><given-names>Z.A.</given-names></name>
<name><surname>Taylor-Brown</surname><given-names>A.</given-names></name>
<name><surname>Chowdhury</surname><given-names>E.K.</given-names></name>
<name><surname>Dougan</surname><given-names>G.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Qadri</surname><given-names>F.</given-names></name>
</person-group><article-title>Genetic diversity of Salmonella Paratyphi A isolated from enteric fever patients in Bangladesh from 2008 to 2018</article-title><source>PLoS Neglected Trop. Dis.</source><year>2021</year><volume>15</volume><elocation-id>e0009748</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0009748</pub-id><pub-id pub-id-type="pmid">34648506</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00122"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McClelland</surname><given-names>M.</given-names></name>
<name><surname>Sanderson</surname><given-names>K.E.</given-names></name>
<name><surname>Clifton</surname><given-names>S.W.</given-names></name>
<name><surname>Latreille</surname><given-names>P.</given-names></name>
<name><surname>Porwollik</surname><given-names>S.</given-names></name>
<name><surname>Sabo</surname><given-names>A.</given-names></name>
<name><surname>Meyer</surname><given-names>R.</given-names></name>
<name><surname>Bieri</surname><given-names>T.</given-names></name>
<name><surname>Ozersky</surname><given-names>P.</given-names></name>
<name><surname>McLellan</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Comparison of genome degradation in Paratyphi A and Typhi, human-restricted serovars of Salmonella enterica that cause typhoid</article-title><source>Nat. Genet.</source><year>2004</year><volume>36</volume><fpage>1268</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1038/ng1470</pub-id><pub-id pub-id-type="pmid">15531882</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00122"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Puyvelde</surname><given-names>S.</given-names></name>
<name><surname>Gasperini</surname><given-names>G.</given-names></name>
<name><surname>Biggel</surname><given-names>M.</given-names></name>
<name><surname>Phoba</surname><given-names>M.F.</given-names></name>
<name><surname>Raso</surname><given-names>M.M.</given-names></name>
<name><surname>de Block</surname><given-names>T.</given-names></name>
<name><surname>Vanheer</surname><given-names>L.N.</given-names></name>
<name><surname>Deborggraeve</surname><given-names>S.</given-names></name>
<name><surname>Vandenberg</surname><given-names>O.</given-names></name>
<name><surname>Thomson</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Genetic and Structural Variation in the O-Antigen of Salmonella enterica Serovar Typhimurium Isolates Causing Bloodstream Infections in the Democratic Republic of the Congo</article-title><source>mBio</source><year>2022</year><volume>13</volume><elocation-id>e0037422</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.00374-22</pub-id><pub-id pub-id-type="pmid">35862803</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00122"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Rondini</surname><given-names>S.</given-names></name>
<name><surname>Alfini</surname><given-names>R.</given-names></name>
<name><surname>Lanzilao</surname><given-names>L.</given-names></name>
<name><surname>Necchi</surname><given-names>F.</given-names></name>
<name><surname>Negrea</surname><given-names>A.</given-names></name>
<name><surname>Rossi</surname><given-names>O.</given-names></name>
<name><surname>Brandt</surname><given-names>C.</given-names></name>
<name><surname>Clare</surname><given-names>S.</given-names></name>
<name><surname>Mastroeni</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>10428</fpage><lpage>10433</lpage><pub-id pub-id-type="doi">10.1073/pnas.1807655115</pub-id><pub-id pub-id-type="pmid">30262653</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00122"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giersing</surname><given-names>B.K.</given-names></name>
<name><surname>Isbrucker</surname><given-names>R.</given-names></name>
<name><surname>Kaslow</surname><given-names>D.C.</given-names></name>
<name><surname>Cavaleri</surname><given-names>M.</given-names></name>
<name><surname>Baylor</surname><given-names>N.</given-names></name>
<name><surname>Maiga</surname><given-names>D.</given-names></name>
<name><surname>Pavlinac</surname><given-names>P.B.</given-names></name>
<name><surname>Riddle</surname><given-names>M.S.</given-names></name>
<name><surname>Kang</surname><given-names>G.</given-names></name>
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries</article-title><source>Lancet Glob. Health</source><year>2023</year><volume>11</volume><fpage>e1819</fpage><lpage>e1826</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(23)00421-7</pub-id><pub-id pub-id-type="pmid">37858591</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00122"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>M.</given-names></name>
<name><surname>Tennant</surname><given-names>S.M.</given-names></name>
<name><surname>Simon</surname><given-names>R.</given-names></name>
<name><surname>Cross</surname><given-names>A.S.</given-names></name>
</person-group><article-title>Progress towards the development of Klebsiella vaccines</article-title><source>Expert. Rev. Vaccines</source><year>2019</year><volume>18</volume><fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1635460</pub-id><pub-id pub-id-type="pmid">31250679</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00122"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kintz</surname><given-names>E.</given-names></name>
<name><surname>Heiss</surname><given-names>C.</given-names></name>
<name><surname>Black</surname><given-names>I.</given-names></name>
<name><surname>Donohue</surname><given-names>N.</given-names></name>
<name><surname>Brown</surname><given-names>N.</given-names></name>
<name><surname>Davies</surname><given-names>M.R.</given-names></name>
<name><surname>Azadi</surname><given-names>P.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Kaye</surname><given-names>P.M.</given-names></name>
<name><surname>van der Woude</surname><given-names>M.</given-names></name>
</person-group><article-title>Salmonella enterica Serovar Typhi Lipopolysaccharide O-Antigen Modification Impact on Serum Resistance and Antibody Recognition</article-title><source>Infect. Immun.</source><year>2017</year><volume>85</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/IAI.01021-16</pub-id><pub-id pub-id-type="pmid">28167670</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00122"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murray</surname><given-names>G.L.</given-names></name>
<name><surname>Attridge</surname><given-names>S.R.</given-names></name>
<name><surname>Morona</surname><given-names>R.</given-names></name>
</person-group><article-title>Regulation of Salmonella typhimurium lipopolysaccharide O antigen chain length is required for virulence; identification of FepE as a second Wzz</article-title><source>Mol. Microbiol.</source><year>2003</year><volume>47</volume><fpage>1395</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03383.x</pub-id><pub-id pub-id-type="pmid">12603743</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00122"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rondini</surname><given-names>S.</given-names></name>
<name><surname>Micoli</surname><given-names>F.</given-names></name>
<name><surname>Lanzilao</surname><given-names>L.</given-names></name>
<name><surname>Gavini</surname><given-names>M.</given-names></name>
<name><surname>Alfini</surname><given-names>R.</given-names></name>
<name><surname>Brandt</surname><given-names>C.</given-names></name>
<name><surname>Clare</surname><given-names>S.</given-names></name>
<name><surname>Mastroeni</surname><given-names>P.</given-names></name>
<name><surname>Saul</surname><given-names>A.</given-names></name>
<name><surname>MacLennan</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar Typhimurium</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>996</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1128/IAI.03079-14</pub-id><pub-id pub-id-type="pmid">25547792</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00122"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baliban</surname><given-names>S.M.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Ramachandran</surname><given-names>G.</given-names></name>
<name><surname>Curtis</surname><given-names>B.</given-names></name>
<name><surname>Shridhar</surname><given-names>S.</given-names></name>
<name><surname>Laufer</surname><given-names>R.S.</given-names></name>
<name><surname>Wang</surname><given-names>J.Y.</given-names></name>
<name><surname>Van Druff</surname><given-names>J.</given-names></name>
<name><surname>Higginson</surname><given-names>E.E.</given-names></name>
<name><surname>Hegerle</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa</article-title><source>PLoS Neglected Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005493</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005493</pub-id></element-citation></ref><ref id="B42-vaccines-13-00122"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jarvis</surname><given-names>F.G.</given-names></name>
<name><surname>Mesenko</surname><given-names>M.T.</given-names></name>
<name><surname>Martin</surname><given-names>D.G.</given-names></name>
<name><surname>Perrine</surname><given-names>T.D.</given-names></name>
</person-group><article-title>Physiochemical properties of the Vi antigen before and after mild alkaline hydrolysis</article-title><source>J. Bacteriol.</source><year>1967</year><volume>94</volume><fpage>1406</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1128/jb.94.5.1406-1410.1967</pub-id><pub-id pub-id-type="pmid">6057799</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00122"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szewczyk</surname><given-names>B.</given-names></name>
<name><surname>Taylor</surname><given-names>A.</given-names></name>
</person-group><article-title>Immunochemical properties of Vi antigen from Salmonella typhi Ty2: Presence of two antigenic determinants</article-title><source>Infect. Immun.</source><year>1980</year><volume>29</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1128/iai.29.2.539-544.1980</pub-id><pub-id pub-id-type="pmid">6163712</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00122"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>De Ricco</surname><given-names>R.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group><article-title>Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>1340</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23061340</pub-id><pub-id pub-id-type="pmid">29865239</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig position="float" id="vaccines-13-00122-sch001"><object-id pub-id-type="pii">vaccines-13-00122-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Step-by-step process of extraction, purification, and analytical characterization of O-antigens from <italic toggle="yes">S.</italic> Paratyphi A strains.</p></caption><graphic xlink:href="vaccines-13-00122-sch001" position="float"/></fig><fig position="float" id="vaccines-13-00122-f001"><label>Figure 1</label><caption><p>HPLC-SEC with the differential refractive index detection profile of ED705 OAg, as a representative isolate. The profile shows the HMW population&#x02019;s peaks and peaks corresponding to the MMW population and core, which are not completely resolved.</p></caption><graphic xlink:href="vaccines-13-00122-g001" position="float"/></fig><fig position="float" id="vaccines-13-00122-f002"><label>Figure 2</label><caption><p>The HPAEC&#x02212;PAD profile of the OAg 01TY544 hydrolyzed after the core&#x02019;s removal, as a representative isolate. The monomers constituting the OAg RU are highlighted: Rha, Gal, Glc, and Man. The calculated Glc/Man nmol ratio gives the glucosylation level of the OAg. The low peak at a retention time of 11.2 min is the glucosamine (GlcNAc) residual coming from the core.</p></caption><graphic xlink:href="vaccines-13-00122-g002" position="float"/></fig><fig position="float" id="vaccines-13-00122-f003"><label>Figure 3</label><caption><p>Individual MFI values for all strains tested in flow cytometry binding assay using sera generated in rabbits with the three O:2 conjugates (<xref rid="vaccines-13-00122-t002" ref-type="table">Table 2</xref>) differing for the O-Acetylation level and the adsorption on Alhydrogel.</p></caption><graphic xlink:href="vaccines-13-00122-g003" position="float"/></fig><fig position="float" id="vaccines-13-00122-f004"><label>Figure 4</label><caption><p>Individual IC50 for all strains tested in L-SBA using sera generated in rabbits with O:2 conjugates differing for the O-Acetylation level, and with adsorbed or minimally adsorbed O-acetylated conjugate.</p></caption><graphic xlink:href="vaccines-13-00122-g004" position="float"/></fig><table-wrap position="float" id="vaccines-13-00122-t001"><object-id pub-id-type="pii">vaccines-13-00122-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical isolates of <italic toggle="yes">Salmonella</italic> Paratyphi A strains and their OAg analytical characterization including OAg production, size, O-acetylation, and glucosylation levels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Isolate ID</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">OAg &#x000b5;g/OD </th><th colspan="2" align="center" valign="middle" style="border-top:solid thin" rowspan="1">Size (kDa)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">%OAc *</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">%Glc *</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HMW</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MMW; Core</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">02TY004</td><td align="center" valign="middle" rowspan="1" colspan="1">307</td><td align="center" valign="middle" rowspan="1" colspan="1">111.3</td><td align="center" valign="middle" rowspan="1" colspan="1">11.4; 3.1</td><td align="center" valign="middle" rowspan="1" colspan="1">90</td><td align="center" valign="middle" rowspan="1" colspan="1">64</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">02TY046</td><td align="center" valign="middle" rowspan="1" colspan="1">396</td><td align="center" valign="middle" rowspan="1" colspan="1">94.4</td><td align="center" valign="middle" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" rowspan="1" colspan="1">61</td><td align="center" valign="middle" rowspan="1" colspan="1">76</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">02TY077</td><td align="center" valign="middle" rowspan="1" colspan="1">255</td><td align="center" valign="middle" rowspan="1" colspan="1">98.5</td><td align="center" valign="middle" rowspan="1" colspan="1">10.1; 2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">75</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">02TY086</td><td align="center" valign="middle" rowspan="1" colspan="1">263</td><td align="center" valign="middle" rowspan="1" colspan="1">84.3</td><td align="center" valign="middle" rowspan="1" colspan="1">11.1; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">02TY187</td><td align="center" valign="middle" rowspan="1" colspan="1">195</td><td align="center" valign="middle" rowspan="1" colspan="1">85.0</td><td align="center" valign="middle" rowspan="1" colspan="1">11.9; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">54</td><td align="center" valign="middle" rowspan="1" colspan="1">51</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">01TY544</td><td align="center" valign="middle" rowspan="1" colspan="1">273</td><td align="center" valign="middle" rowspan="1" colspan="1">96.3</td><td align="center" valign="middle" rowspan="1" colspan="1">13.0; 3.2</td><td align="center" valign="middle" rowspan="1" colspan="1">87</td><td align="center" valign="middle" rowspan="1" colspan="1">89</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ED705</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">975</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td><td align="center" valign="middle" rowspan="1" colspan="1">49</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ED766</td><td align="center" valign="middle" rowspan="1" colspan="1">139</td><td align="center" valign="middle" rowspan="1" colspan="1">91.6</td><td align="center" valign="middle" rowspan="1" colspan="1">10.4; 2.7</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">79</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ED768</td><td align="center" valign="middle" rowspan="1" colspan="1">245</td><td align="center" valign="middle" rowspan="1" colspan="1">92.0</td><td align="center" valign="middle" rowspan="1" colspan="1">11.0; 2.5</td><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1">95</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ATCC9150</td><td align="center" valign="middle" rowspan="1" colspan="1">44</td><td align="center" valign="middle" rowspan="1" colspan="1">99.7</td><td align="center" valign="middle" rowspan="1" colspan="1">6.6; 2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">57</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NVGH308</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">219</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78</td></tr></tbody></table><table-wrap-foot><fn><p>* % OAc and % Glc are expressed as molar ratio % with respect to RU.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00122-t002"><object-id pub-id-type="pii">vaccines-13-00122-t002_Table 2</object-id><label>Table 2</label><caption><p>An overview of the three different O:2-CRM<sub>197</sub> formulations synthetized in the Alfini et al. study [<xref rid="B21-vaccines-13-00122" ref-type="bibr">21</xref>], differing by O-acetylation level and adsorption on Alhydrogel.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Entry <italic toggle="yes">n</italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conjugate Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">O:2 O-Acetylation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Conjugate Adsorption on Alhydrogel</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Osmolality<break/>mOsm/kg</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pH</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">O:2-CRM<sub>197</sub>&#x02013;55.6% OAc</td><td align="center" valign="middle" rowspan="1" colspan="1">55.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">98.1%</td><td align="center" valign="middle" rowspan="1" colspan="1">278</td><td align="center" valign="middle" rowspan="1" colspan="1">7.76</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">O:2-CRM<sub>197</sub>&#x02013;not OAc</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">99.0%</td><td align="center" valign="middle" rowspan="1" colspan="1">298</td><td align="center" valign="middle" rowspan="1" colspan="1">7.45</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O:2-CRM<sub>197</sub>&#x02013;55.6% OAc&#x02013;minimally adsorbed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.6%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">282</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.67</td></tr></tbody></table></table-wrap></sec></back></article>